Related Experiment Video
Updated: Apr 3, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.7K
Update on reslizumab for eosinophilic asthma
Juan Carlos Cardet1,2,3, Elliot Israel4
1a 1 Harvard Medical School , Boston, MA, USA.
Expert Opinion on Biological Therapy
|September 16, 2015
Summary
Reslizumab, an anti-interleukin-5 (IL-5) therapy, effectively reduces exacerbations and improves symptoms in severe eosinophilic asthma. Patient selection based on eosinophil counts enhances treatment efficacy and safety.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Severe eosinophilic asthma presents a significant unmet medical need.
- Reslizumab targets the interleukin-5 (IL-5) pathway, a key driver of eosinophilic inflammation in asthma.
- Monoclonal antibodies like reslizumab offer a novel therapeutic approach.
Purpose of the Study:
- To review clinical trial data on reslizumab for treating eosinophilic asthma.
- To discuss the role of eosinophils and IL-5 in asthma pathogenesis.
- To evaluate the efficacy and safety of reslizumab.
Main Methods:
- Literature review of clinical trials involving reslizumab.
- Searches conducted on PubMed and ClinicalTrials.gov using relevant keywords.
- Analysis of data regarding asthma exacerbations, symptoms, and pulmonary function.
Main Results:
- Reslizumab demonstrated reductions in asthma exacerbations in Phase IIIb trials.
- The therapy improved asthma-related symptoms and pulmonary function.
- Participant selection based on eosinophil counts improved trial outcomes.
Conclusions:
- Reslizumab and other anti-IL-5 therapies show promise for severe eosinophilic asthma.
- Targeted selection of patients with eosinophilic inflammation is crucial for efficacy.
- While safety is good, long-term data are pending; approval is anticipated.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.3K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
01:20Asthma: Pathogenesis and Management
1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
2.2K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.2K